F10 and coronary artery disorder: In the most recent Cardiovascular Outcomes for People Using Anticoagulation Strategies [74] trial, the role of factor Xa inhibition with Rvaroxaban was tested among chronic and stabilized patients with coronary artery disease (CAD) and in peripheral arterial disease (PAD) [74].